

# David J Brooks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8427021/david-j-brooks-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330 papers	36,476 citations	94 h-index	185 g-index
373 ext. papers	41,823 ext. citations	7.8 avg, IF	7 L-index

#	Paper	IF	Citations
330	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
329	Capillary function progressively deteriorates in prodromal Alzheimer's disease: A longitudinal MRI perfusion study. <i>Aging Brain</i> , <b>2022</b> , 2, 100035		0
328	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [F]FEOBV PET/CT study.. <i>EJNMMI Research</i> , <b>2022</b> , 12, 17	3.6	1
327	PET Imaging of Translocator Protein Expression in Neurological Disorders <b>2021</b> , 1021-1040		1
326	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [C]UCB-J PET Imaging Study. <i>Movement Disorders</i> , <b>2021</b> , 36, 2057-2065	7	10
325	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. <i>Brain</i> , <b>2021</b> , 144, 1498-1508	11.2	1
324	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. <i>Neurobiology of Disease</i> , <b>2021</b> , 152, 105295	7.5	2
323	In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 41, 819-830	7.3	9
322	Progression of sleep disturbances in Parkinson's disease: a 5-year longitudinal study. <i>Journal of Neurology</i> , <b>2021</b> , 268, 312-320	5.5	12
321	NMDA receptor ion channel activation detected in vivo with [F]GE-179 PET after electrical stimulation of rat hippocampus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2021</b> , 41, 1301-1312	7.3	8
320	Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 774-779	7	19
319	Future Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , <b>2021</b> , 51, 303-308	5.4	1
318	Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism. <i>Neurotherapeutics</i> , <b>2021</b> , 18, 753-771	6.4	1
317	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. <i>Neurobiology of Disease</i> , <b>2021</b> , 149, 105229	7.5	14
316	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 47	9	14
315	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	5
314	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 1677-1687	5.3	7

313	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. <i>Brain</i> , <b>2021</b> , 144, 2732-2744	11.2	7
312	The Cholinergic Brain in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 1012-1026	2.2	10
311	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 90, 52-56	3.6	2
310	Activated N-methyl-D-aspartate receptor ion channels detected in focal epilepsy with [F]GE-179 positron emission tomography. <i>Epilepsia</i> , <b>2021</b> , 62, 2899-2908	6.4	0
309	Neuroinflammation, functional connectivity and structural network integrity in the Alzheimer's spectrum.. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17 Suppl 3, e055970	1.2	
308	Microglial activation evaluated using flutriciclamide (11F-GE180) in subjects with cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045465	1.2	
307	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e046045	1.2	
306	The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 151	10.1	45
305	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 1885-1912	8.8	57
304	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2242-2243	8.8	3
303	Impaired perfusion and capillary dysfunction in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12032	5.2	5
302	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder - A PET study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 75, 63-69	3.6	8
301	Preclinical PET Studies of [C]UCB-J Binding in Minipig Brain. <i>Molecular Imaging and Biology</i> , <b>2020</b> , 22, 1290-1300	3.8	3
300	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2296-2300	5.5	7
299	Influence of microglial activation on structural and functional connectivity in mild cognitive impairment subjects. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042990	1.2	
298	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 3	9	10
297	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 161-171	5.3	3
296	In Response to Letter from Fregonara et al. 2019. <i>Molecular Imaging and Biology</i> , <b>2020</b> , 22, 13-14	3.8	2

295	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 951-962	24.1	95
294	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 81, 89-93	3.6	6
293	Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. <i>Brain</i> , <b>2020</b> , 143, 3077-3088	11.2	130
292	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 750-762	2.2	13
291	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 327-332	5.2	6
290	Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold. <i>Journal of Neuroimaging</i> , <b>2019</b> , 29, 499-505	2.8	7
289	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). <i>Trials</i> , <b>2019</b> , 20, 191	2.8	57
288	Attenuation of dopamine-induced GABA release in problem gamblers. <i>Brain and Behavior</i> , <b>2019</b> , 9, e012394	3.4	10
287	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. <i>Molecular Imaging and Biology</i> , <b>2019</b> , 21, 935-944	3.8	27
286	Dynamic C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1452-1460	8.9	27
285	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. <i>Neurology</i> , <b>2019</b> , 92, e1331-e1343	6.5	39
284	Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , <b>2019</b> , 34, 564-568	7	21
283	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 15758	4.9	8
282	Comment on "In Vivo [F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 768-772	5.7	10
281	Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. <i>Experimental Neurology</i> , <b>2018</b> , 303, 142-152	5.7	20
280	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. <i>Clinical Neurophysiology</i> , <b>2018</b> , 129, 541-547	4.3	8
279	Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. <i>Brain</i> , <b>2018</b> , 141, 496-504	11.2	80
278	Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1528-1539	5.5	24

277	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\tau$ -positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
276	Extrastratial monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. <i>Neurobiology of Disease</i> , <b>2018</b> , 115, 9-16	7.5	18
275	Parametric mapping using spectral analysis for C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1432-1441	8.8	19
274	Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. <i>Movement Disorders</i> , <b>2018</b> , 33, 909-919	7	56
273	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 2740-2754	11.2	93
272	In vivo quantification of glial activation in minipigs overexpressing human $\beta$ -synuclein. <i>Synapse</i> , <b>2018</b> , 72, e22060	2.4	9
271	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. <i>Neurobiology of Disease</i> , <b>2018</b> , 117, 211-216	7.5	34
270	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
269	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([F]-AV-1451) Binding. <i>Molecular Imaging and Biology</i> , <b>2018</b> , 20, 356-360	3.8	37
268	Simplifying [F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. <i>EJNMMI Research</i> , <b>2018</b> , 8, 46	3.6	3
267	The Future of Brain Imaging in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, S47-S51	5.3	18
266	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , <b>2018</b> , 2018, 6852303	3.7	13
265	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. <i>Movement Disorders</i> , <b>2018</b> , 33, 1006-1010	7	19
264	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 618-628	24.1	135
263	Role of Neuroinflammation in the Trajectory of Alzheimer's Disease and in vivo Quantification Using PET. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, S339-S351	4.3	17
262	Decreased intestinal acetylcholinesterase in early Parkinson disease: An C-donepezil PET study. <i>Neurology</i> , <b>2017</b> , 88, 775-781	6.5	54
261	Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 1702-1715	5.9	29
260	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. <i>Movement Disorders</i> , <b>2017</b> , 32, 922-927	7	32

259	An early and late peak in microglial activation in Alzheimer's disease trajectory. <i>Brain</i> , <b>2017</b> , 140, 792-803	11.2	156
258	Imaging Parkinson's disease below the neck. <i>Npj Parkinson's Disease</i> , <b>2017</b> , 3, 15	9.7	9
257	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. <i>Brain</i> , <b>2017</b> , 140, 2002-2011	11.2	105
256	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 55, 78-90	5.6	30
255	Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , <b>2017</b> , 16, 455-460	5.3	24
254	[P1030]: DIFFERENT MODELLING APPROACHES FOR TAU TRACER 18F-AV1451 IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE <b>2017</b> , 13, P291-P292		
253	[P2097]: AMYLOID DEPOSITION, TAU AGGREGATION AND MICROGLIAL ACTIVATION CORRELATE WITH VASCULAR BURDEN IN VIVO IN ALZHEIMER'S DISEASE <b>2017</b> , 13, P681-P682		1
252	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. <i>Lancet Neurology</i> , <b>2017</b> , 16, 789-796	24.1	98
251	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , <b>2017</b> , 32, 235-240	7	14
250	[P4065]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL <b>2017</b> , 13, P1385-P1385		
249	[IC-P-074]: LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAINS DECLINE IN EARLY STAGE PARKINSON'S DISEASE: ICICLE-PD STUDY <b>2017</b> , 13, P61-P61		
248	[O10201]: [18F]FLUTEMETAMOL AMYLOID SCANNING IN A PHASE III AMNESTIC MILD COGNITIVE IMPAIRMENT STUDY: ADDITIONAL INFLUENCE OF OTHER BIOMARKERS IN ESTIMATING RISK OF CONVERSION TO PROBABLE ALZHEIMERS DISEASE <b>2017</b> , 13, P221		1
247	[IC-P-088]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL <b>2017</b> , 13, P71-P72		
246	Imaging biomarkers in tauopathies. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 22 Suppl 1, S26-8	3.6	22
245	Imaging of genetic and degenerative disorders primarily causing Parkinsonism. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2016</b> , 135, 493-505	3	3
244	Kinetic analysis of the translocator protein positron emission tomography ligand [F]GE-180 in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 2201-2210	8.8	57
243	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , <b>2016</b> , 87, 2451-2456	6.5	30
242	Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1753-1759	8.9	75

241	Molecular imaging of dopamine transporters. <i>Ageing Research Reviews</i> , <b>2016</b> , 30, 114-21	12	61
240	Age at onset and Parkinson disease phenotype. <i>Neurology</i> , <b>2016</b> , 86, 1400-1407	6.5	157
239	Amyloid pathology and axonal injury after brain trauma. <i>Neurology</i> , <b>2016</b> , 86, 821-8	6.5	86
238	Imaging synucleinopathies. <i>Movement Disorders</i> , <b>2016</b> , 31, 814-29	7	24
237	Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 51, 1275-89	4.3	40
236	Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. <i>NeuroImage</i> , <b>2016</b> , 132, 1-7	7.9	7
235	Imaging Systemic Dysfunction in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , <b>2016</b> , 16, 51	6.6	16
234	In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. <i>Brain</i> , <b>2016</b> , 139, 2039-49	11.2	95
233	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1062-6	7	36
232	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , <b>2015</b> , 138, 2974-86	11.2	146
231	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1736-1742	5.6	39
230	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
229	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1939-49	27.4	379
228	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , <b>2015</b> , 14, 388-405	24.1	2760
227	Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. <i>Brain</i> , <b>2015</b> , 138, 3685-98	11.2	82
226	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 707-13	8.9	26
225	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 608-21.e7	1.2	121
224	Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 224	10.1	39



223	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 743-7	5.3	12
222	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1110-20	1.2	57
221	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. <i>Brain</i> , <b>2015</b> , 138, 653-63	11.2	103
220	Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [ <sup>11</sup> C]MePPEP. <i>NeuroImage</i> , <b>2014</b> , 97, 151-62	7.9	15
219	Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 423-30	8.9	58
218	What can biomarkers tell us about cognition in Parkinson's disease?. <i>Movement Disorders</i> , <b>2014</b> , 29, 622-33	3.3	48
217	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. <i>Frontiers in Behavioral Neuroscience</i> , <b>2014</b> , 8, 86	3.5	18
216	Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. <i>Neurology</i> , <b>2014</b> , 82, 308-16	6.5	288
215	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 1340-9	15.9	172
214	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. <i>Aids</i> , <b>2014</b> , 28, 67-72	3.5	95
213	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. <i>Brain</i> , <b>2014</b> , 137, 2743-58	11.2	109
212	Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. <i>Movement Disorders</i> , <b>2014</b> , 29, 195-202	7	224
211	In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: dosimetry, biodistribution, and kinetic analyses. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1818-24	8.9	35
210	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid $\beta$ amyloid 42: a cross-validation study against amyloid positron emission tomography. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1282-9	17.2	254
209	Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. <i>Addiction Biology</i> , <b>2014</b> , 19, 1032-40	4.6	19
208	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 104-14	8.8	148
207	Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 1-11	5.3	67
206	The spectrum of nonmotor symptoms in early Parkinson disease. <i>Neurology</i> , <b>2013</b> , 80, 276-81	6.5	281



205	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , <b>2013</b> , 81, 487-500	6.5	173
204	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 527-32	3.6	17
203	Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. <i>Neuropsychopharmacology</i> , <b>2013</b> , 38, 938-49	8.7	158
202	Quantification of opioid receptor availability following spontaneous epileptic seizures: correction of [11C]diprenorphine PET data for the partial-volume effect. <i>NeuroImage</i> , <b>2013</b> , 79, 72-80	7.9	14
201	Binary classification of $^{18}$ F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI. <i>NeuroImage</i> , <b>2013</b> , 64, 517-25	7.9	37
200	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. <i>Neurology</i> , <b>2013</b> , 80, 1850-5	6.5	76
199	Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. <i>Neurology</i> , <b>2013</b> , 81, 1176-8	6.5	42
198	The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 657-65	5.5	73
197	Reference region automatic extraction in dynamic [(11)C]PIB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 1725-31	7.3	18
196	Bad news for neuroprotective therapies in PD?. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 271-3	5.3	1
195	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. <i>PLoS ONE</i> , <b>2013</b> , 8, e57221	3.7	73
194	Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. <i>Frontiers in Psychology</i> , <b>2013</b> , 4, 90	3.4	15
193	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , <b>2012</b> , 11, 241-9	24.1	307
192	Brain monoamine systems in multiple system atrophy: a positron emission tomography study. <i>Neurobiology of Disease</i> , <b>2012</b> , 46, 130-6	7.5	30
191	Parkinson's disease: diagnosis. <i>Parkinsonism and Related Disorders</i> , <b>2012</b> , 18 Suppl 1, S31-3	3.6	38
190	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , <b>2012</b> , 259, 1639-47	5.5	153
189	Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. <i>Neurodegenerative Diseases</i> , <b>2012</b> , 10, 246-9	2.3	51
188	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. <i>Archives of Neurology</i> , <b>2012</b> , 69, 198-207		288

187	Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. <i>PLoS ONE</i> , <b>2012</b> , 7, e38980	3.7	27
186	The prognostic value of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1207-19	8.8	26
185	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 128ra41	17.5	92
184	<sup>11</sup> C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 340-1	5.5	8
183	A [ <sup>11</sup> C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced $\alpha$ benzodiazepine receptors in limbic regions. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 273-81	4.6	39
182	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. <i>Brain</i> , <b>2012</b> , 135, 2449-57	11.2	52
181	Characterisation of the contribution of the GABA-benzodiazepine $\alpha$ receptor subtype to [(11)C]Ro15-4513 PET images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2012</b> , 32, 731-44	7.3	24
180	Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal <sup>18</sup> F-dopa PET study. <i>NeuroImage</i> , <b>2011</b> , 56, 1463-8	7.9	105
179	Imaging biomarkers in Parkinson's disease. <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 614-28	10.9	134
178	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 629-35	10.9	793
177	Serotonergic mediated body mass index changes in Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2011</b> , 43, 609-15	7.5	36
176	Milestones in neuroimaging. <i>Movement Disorders</i> , <b>2011</b> , 26, 868-978	7	7
175	Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. <i>Movement Disorders</i> , <b>2011</b> , 26, 1997-2003	7	126
174	Inflammation after trauma: microglial activation and traumatic brain injury. <i>Annals of Neurology</i> , <b>2011</b> , 70, 374-83	9.4	623
173	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. <i>Human Brain Mapping</i> , <b>2011</b> , 32, 258-70	5.9	147
172	Apathy blunts neural response to money in Parkinson's disease. <i>Social Neuroscience</i> , <b>2011</b> , 6, 653-62	2	33
171	Technical aspects of amyloid imaging for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2011</b> , 3, 25	9	7
170	Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. <i>Brain</i> , <b>2011</b> , 134, 979-86	11.2	152

169	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. <i>Brain</i> , <b>2011</b> , 134, 293-300	11.2	75
168	Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 735-43	8.7	21
167	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 38ra46	17.5	231
166	Imaging dopamine transporters in Parkinson's disease. <i>Biomarkers in Medicine</i> , <b>2010</b> , 4, 651-60	2.3	30
165	Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. <i>Brain</i> , <b>2010</b> , 133, 3434-43	11.2	224
164	Imaging approaches to Parkinson disease. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 596-609	8.9	139
163	GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1030-5	8.9	101
162	In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. <i>Experimental Neurology</i> , <b>2010</b> , 222, 120-4	5.7	22
161	Imaging non-motor aspects of Parkinson's disease. <i>Progress in Brain Research</i> , <b>2010</b> , 184, 205-18	2.9	20
160	An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. <i>Clinical Neuropharmacology</i> , <b>2010</b> , 33, 55-60	1.4	44
159	11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , <b>2010</b> , 9, 363-72	24.1	589
158	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , <b>2010</b> , 37, 356-61	7.5	49
157	Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , <b>2010</b> , 40, 216-21	7.5	179
156	18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. <i>Annals of Neurology</i> , <b>2010</b> , 68, 319-29	9.4	475
155	Examining Braak's hypothesis by imaging Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25 Suppl 1, S83-8	7	19
154	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , <b>2010</b> , 25, 97-107	7	136
153	Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 818-22	8.9	175
152	Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 1251-9	8.9	231

151	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 655-61	7	245
150	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. <i>Movement Disorders</i> , <b>2009</b> , 24, 949-64	7	119
149	Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. <i>Movement Disorders</i> , <b>2009</b> , 24 Suppl 2, S742-7	7	69
148	Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. <i>Movement Disorders</i> , <b>2009</b> , 24, 2260-6	7	36
147	The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1693-4	8.8	6
146	Imaging neurodegeneration in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2009</b> , 1792, 722-9	6.9	85
145	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 740-8	1.2	58
144	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. <i>NeuroImage</i> , <b>2009</b> , 48, 329-38	7.9	21
143	Recent imaging advances in the diagnosis and management of Parkinson's disease. <i>F1000 Medicine Reports</i> , <b>2009</b> , 1,		6
142	[11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2008</b> , 28, 207-16	7.3	30
141	Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. <i>Neurobiology of Disease</i> , <b>2008</b> , 29, 381-90	7.5	96
140	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. <i>Neurobiology of Disease</i> , <b>2008</b> , 32, 412-9	7.5	395
139	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. <i>Brain</i> , <b>2008</b> , 131, 1294-302	11.2	204
138	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. <i>Experimental Neurology</i> , <b>2008</b> , 214, 112-6	5.7	84
137	Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shunting--A retrospective analysis of [(15)O]H(2)O PET-CBF studies in 65 patients. <i>Clinical Neurology and Neurosurgery</i> , <b>2008</b> , 110, 369-75	2	64
136	Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1249-56	8.9	73
135	The role of structural and functional imaging in parkinsonian states with a description of PET technology. <i>Seminars in Neurology</i> , <b>2008</b> , 28, 435-45	3.2	15
134	Technology insight: imaging neurodegeneration in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , <b>2008</b> , 4, 267-77		28

133	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , <b>2008</b> , 9, 43-9		41
132	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , <b>2008</b> , 193, 65-72	5.4	53
131	Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. <i>Neuropsychiatric Disease and Treatment</i> , <b>2008</b> , 4, 39-47	3.1	73
130	Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2008</b> , 115, 843-9	4.3	21
129	Imaging Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2007</b> , 83, 245-63	3	
128	Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. <i>British Journal of Psychiatry</i> , <b>2007</b> , 191, 63-9	5.4	58
127	Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. <i>Human Brain Mapping</i> , <b>2007</b> , 28, 34-48	5.9	53
126	Reply: Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 1522-1522	7	
125	STN stimulation alters pallidal-frontal coupling during response selection under competition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2007</b> , 27, 1173-84	7.3	59
124	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. <i>Neuropsychologia</i> , <b>2007</b> , 45, 65-74	3.2	130
123	Imaging non-dopaminergic function in Parkinson's disease. <i>Molecular Imaging and Biology</i> , <b>2007</b> , 9, 217-228		32
122	Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. <i>Journal of Neurology</i> , <b>2007</b> , 254, 1033-6	5.5	33
121	Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. <i>Journal of Neurology</i> , <b>2007</b> , 254, IV37-IV48	5.5	9
120	Upregulation of opioid receptor binding following spontaneous epileptic seizures. <i>Brain</i> , <b>2007</b> , 130, 1009-16	11.6	84
119	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , <b>2007</b> , 8, 343-7		39
118	Microglial activation in presymptomatic Huntington's disease gene carriers. <i>Brain</i> , <b>2007</b> , 130, 1759-66	11.2	324
117	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2007</b> , 78, 825-31	5.5	68
116	Imaging microglial activation in Huntington's disease. <i>Brain Research Bulletin</i> , <b>2007</b> , 72, 148-51	3.9	103

115	A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. <i>NeuroImage</i> , <b>2007</b> , 36, 28-37	7.9	33
114	Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. <i>NeuroImage</i> , <b>2007</b> , 38, 261-70	7.9	84
113	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [(11)C]diprenorphine test-retest data. <i>NeuroImage</i> , <b>2007</b> , 38, 82-94	7.9	41
112	Assessment of Parkinson's disease with imaging. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13 Suppl 3, S268-75	3.6	18
111	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology, The</i> , <b>2006</b> , 5, 200-2	24.1	29
110	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2006</b> , 21, 404-12	7.5	806
109	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2006</b> , 21, 89-93	7	144
108	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. <i>Movement Disorders</i> , <b>2006</b> , 21, 299-305	7	17
107	Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. <i>Movement Disorders</i> , <b>2006</b> , 21, 783-8	7	27
106	New developments of brain imaging for Parkinson's disease and related disorders. <i>Movement Disorders</i> , <b>2006</b> , 21, 2035-41	7	31
105	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , <b>2006</b> , 21, 1844-50	116	
104	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , <b>2006</b> , 59, 459-66	9.4	785
103	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , <b>2006</b> , 59, 852-8	9.4	359
102	Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. <i>Annals of Neurology</i> , <b>2006</b> , 60, 145-7	9.4	163
101	Imaging in Parkinson's disease: the role of monoamines in behavior. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 908-18	116	
100	Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. <i>Wiener Klinische Wochenschrift</i> , <b>2006</b> , 118, 570-2	2.3	7
99	Dopaminergic action beyond its effects on motor function: imaging studies. <i>Journal of Neurology</i> , <b>2006</b> , 253 Suppl 4, IV8-15	5.5	14
98	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. <i>Brain</i> , <b>2005</b> , 128, 2786-96	11.2	283



97	Imaging studies in drug development: Parkinson's disease. <i>Drug Discovery Today: Technologies</i> , <b>2005</b> , 2, 317-21	7.1	1
96	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. <i>NeuroRx</i> , <b>2005</b> , 2, 226-36		85
95	Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. <i>Epilepsia</i> , <b>2005</b> , 46, 944-8	6.4	31
94	Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. <i>Nature Medicine</i> , <b>2005</b> , 11, 703-4	50.5	225
93	Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. <i>Annals of Neurology</i> , <b>2005</b> , 57, 634-41	9.4	42
92	Chorea associated with thyroxine replacement therapy. <i>Movement Disorders</i> , <b>2005</b> , 20, 1656-7	7	27
91	Using [ <sup>11</sup> C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 312, 309-15	4.7	57
90	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. <i>Brain</i> , <b>2005</b> , 128, 2977-86	11.2	205
89	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. <i>Brain</i> , <b>2005</b> , 128, 1314-22	11.2	757
88	The role of opioids in restless legs syndrome: an [ <sup>11</sup> C]diprenorphine PET study. <i>Brain</i> , <b>2005</b> , 128, 906-17	11.2	114
87	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. <i>Neurotherapeutics</i> , <b>2005</b> , 2, 226-236	6.4	
86	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [ <sup>11</sup> C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S591-S591	7.3	
85	Towards improved test-retest reliability in quantitative ligand PET: [ <sup>11</sup> C]Diprenorphine as an example. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2005</b> , 25, S665-S665	7.3	2
84	Reward processing in health and Parkinson's disease: neural organization and reorganization. <i>Cerebral Cortex</i> , <b>2004</b> , 14, 73-80	5.1	38
83	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. <i>Brain</i> , <b>2004</b> , 127, 1332-42	11.2	92
82	Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. <i>Neuropsychologia</i> , <b>2004</b> , 42, 1917-26	3.2	29
81	The human premotor cortex is 'mirror' only for biological actions. <i>Current Biology</i> , <b>2004</b> , 14, 117-20	6.3	259
80	Cardiovascular effects of methamphetamine in Parkinson's disease patients. <i>Movement Disorders</i> , <b>2004</b> , 19, 298-303	7	10



79	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. <i>Movement Disorders</i> , <b>2004</b> , 19, 1221-6	7	117
78	Opioid binding in DYT1 primary torsion dystonia: an 11C-diprenorphine PET study. <i>Movement Disorders</i> , <b>2004</b> , 19, 1498-503	7	14
77	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. <i>Biological Psychiatry</i> , <b>2004</b> , 55, 904-15	7.9	43
76	Positron emission tomography imaging of transplant function. <i>NeuroRx</i> , <b>2004</b> , 1, 482-91		17
75	Neuroimaging in Parkinson's disease. <i>NeuroRx</i> , <b>2004</b> , 1, 243-54		72
74	Safety and tolerability of COMT inhibitors. <i>Neurology</i> , <b>2004</b> , 62, S39-46	6.5	48
73	Neuroimaging in Parkinson's disease. <i>Neurotherapeutics</i> , <b>2004</b> , 1, 243-254	6.4	
72	Positron emission tomography imaging of transplant function. <i>Neurotherapeutics</i> , <b>2004</b> , 1, 482-491	6.4	
71	PET studies on the function of dopamine in health and Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 991, 22-35	6.5	31
70	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. <i>Brain</i> , <b>2003</b> , 126, 1127-35	11.2	180
69	Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. <i>Brain</i> , <b>2003</b> , 126, 1300-18	11.2	70
68	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. <i>Brain</i> , <b>2003</b> , 126, 312-25	11.2	81
67	Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. <i>Brain Research</i> , <b>2003</b> , 982, 137-45	3.7	71
66	Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. <i>Human Brain Mapping</i> , <b>2003</b> , 19, 224-47	5.9	797
65	Plasticity of the nigropallidal pathway in Parkinson's disease. <i>Annals of Neurology</i> , <b>2003</b> , 53, 206-13	9.4	132
64	Imaging end points for monitoring neuroprotection in Parkinson's disease. <i>Annals of Neurology</i> , <b>2003</b> , 53 Suppl 3, S110-8; discussion S118-9	9.4	39
63	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. <i>Annals of Neurology</i> , <b>2003</b> , 53, 647-53	9.4	136
62	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , <b>2003</b> , 54, 93-101	9.4	691

61	Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. <i>Nature Medicine</i> , <b>2003</b> , 9, 589-95	50.5	1095
60	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. <i>Brain</i> , <b>2002</b> , 125, 2248-56	11.2	120
59	Increased dopamine tone during meditation-induced change of consciousness. <i>Cognitive Brain Research</i> , <b>2002</b> , 13, 255-9		222
58	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <i>Annals of Neurology</i> , <b>2002</b> , 52, 849-53	9.4	179
57	An imaging study of parkinsonism among African-Caribbean and Indian London communities. <i>Movement Disorders</i> , <b>2002</b> , 17, 1321-8	7	13
56	Implementation and application of a brain template for multiple volumes of interest. <i>Human Brain Mapping</i> , <b>2002</b> , 15, 165-74	5.9	73
55	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. <i>Synapse</i> , <b>2002</b> , 43, 201-7	2.4	86
54	Dyskinesias following neural transplantation in Parkinson's disease. <i>Nature Neuroscience</i> , <b>2002</b> , 5, 627-8	25.5	365
53	Diagnosis and management of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2002</b> , 72 Suppl 1, I10-I16	5.5	24
52	Updated guidelines for the management of Parkinson's disease. <i>British Journal of Hospital Medicine</i> , <b>2001</b> , 62, 456-70		19
51	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. <i>Movement Disorders</i> , <b>2001</b> , 16, 382-395	7	6
50	Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. <i>Movement Disorders</i> , <b>2001</b> , 16, 1014-22	7	94
49	Global Increase in Cortical Opioid Binding Potential with Aging: In Vivo Quantification with 11C diprenorphine PET. <i>Psychogeriatrics</i> , <b>2001</b> , 1, 309-316	1.8	1
48	In-vivo measurement of activated microglia in dementia. <i>Lancet, The</i> , <b>2001</b> , 358, 461-7	40	861
47	Non-invasive in vivo imaging of transplant function. <i>Progress in Brain Research</i> , <b>2000</b> , 127, 321-32	2.9	2
46	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , <b>2000</b> , 48, 689-695	9.4	211
45	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. <i>Movement Disorders</i> , <b>2000</b> , 15, 224-9	7	40
44	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2000</b> , 15, 446-458	7	26

43	Imaging basal ganglia function. <i>Journal of Anatomy</i> , <b>2000</b> , 196 ( Pt 4), 543-54	2.9	24
42	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1484-91	59.2	1253
41	Identification of the cerebral loci processing human swallowing with H2(15)O PET activation. <i>Journal of Neurophysiology</i> , <b>1999</b> , 81, 1917-26	3.2	291
40	Huntington's disease progression. PET and clinical observations. <i>Brain</i> , <b>1999</b> , 122 ( Pt 12), 2353-63	11.2	181
39	Mapping the network for planning: a correlational PET activation study with the Tower of London task. <i>Brain</i> , <b>1999</b> , 122 ( Pt 10), 1973-87	11.2	311
38	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. <i>Nature Neuroscience</i> , <b>1999</b> , 2, 1137-40	25.5	582
37	The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1999</b> , 19, 673-8	7.3	51
36	A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. <i>Metabolic Brain Disease</i> , <b>1999</b> , 14, 45-55	3.9	44
35	The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. <i>Annals of Neurology</i> , <b>1999</b> , 45, 577-82	9.4	275
34	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. <i>Hippocampus</i> , <b>1999</b> , 9, 247-54	3.5	80
33	Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. <i>Lancet, The</i> , <b>1999</b> , 353, 1662-7	4.0	246
32	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology <b>1999</b> , 9, 247		1
31	Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. <i>Trends in Molecular Medicine</i> , <b>1998</b> , 4, 532-9		33
30	In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. <i>Annals of Neurology</i> , <b>1998</b> , 43, 618-26	9.4	55
29	Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. <i>Movement Disorders</i> , <b>1998</b> , 13, 39-45	7	234
28	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. <i>Movement Disorders</i> , <b>1998</b> , 13, 46-51	7	115
27	Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. <i>Movement Disorders</i> , <b>1998</b> , 13, 309-18	7	87
26	Dopamine agonists and neuroprotection in Parkinson's disease. <i>Annals of Neurology</i> , <b>1998</b> , 44, S167-74	9.4	85

25	Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. <i>British Journal of Psychiatry</i> , <b>1998</b> , 172, 316-23	5.4	96
24	The effect of movement frequency on cerebral activation: a positron emission tomography study. <i>Journal of the Neurological Sciences</i> , <b>1997</b> , 151, 195-205	3.2	79
23	Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. <i>Epilepsia</i> , <b>1997</b> , 38, 1089-97	6.4	75
22	11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1997</b> , 17, 943-9	7.3	68
21	Stereotactic thalamotomy in tremor-dominant Parkinson's disease: an H2(15)O PET motor activation study. <i>Annals of Neurology</i> , <b>1997</b> , 41, 108-11	9.4	54
20	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <i>Annals of Neurology</i> , <b>1997</b> , 42, 95-107	9.4	276
19	Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. <i>Movement Disorders</i> , <b>1997</b> , 12, 691-6	7	47
18	Parkinsonism associated with acute intracranial hematomas: an [18F]dopa positron-emission tomography study. <i>Movement Disorders</i> , <b>1997</b> , 12, 1035-8	7	32
17	Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. <i>Nuclear Medicine and Biology</i> , <b>1996</b> , 23, 377-84	2.1	17
16	Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. <i>Synapse</i> , <b>1995</b> , 21, 45-53	2.4	89
15	Benzodiazepine-GABAA receptors in idiopathic generalized epilepsy measured with [11C]flumazenil and positron emission tomography. <i>Epilepsia</i> , <b>1995</b> , 36, 113-21	6.4	41
14	Benzodiazepine-GABAA receptor binding during absence seizures. <i>Epilepsia</i> , <b>1995</b> , 36, 592-9	6.4	27
13	L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. <i>Movement Disorders</i> , <b>1995</b> , 10, 241-9	7	47
12	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. <i>Annals of Neurology</i> , <b>1994</b> , 35, 172-80	9.4	326
11	Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. <i>Annals of Neurology</i> , <b>1994</b> , 35, 298-303	9.4	47
10	Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. <i>Synapse</i> , <b>1992</b> , 12, 47-54	2.4	183
9	Core assessment program for intracerebral transplantations (CAPIT). <i>Movement Disorders</i> , <b>1992</b> , 7, 2-13	7	683
8	PET: Motor function and dysfunction. <i>Movement Disorders</i> , <b>1992</b> , 7, 20-20	7	1

7	Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. <i>Annals of Neurology</i> , <b>1992</b> , 31, 166-73	9.4	279
6	The clinical role of PET in cerebrovascular disease. <i>Neurosurgical Review</i> , <b>1991</b> , 14, 91-6	3.9	9
5	A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1990</b> , 10, 307-16	7.3	64
4	Measurement of regional cerebral pH in human subjects using continuous inhalation of 11CO <sub>2</sub> and positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1984</b> , 4, 458-65	7.3	47
3	Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>1984</b> , 4, 535-45	7.3	73
2	Positron emission tomography in the study of cerebral tumours. <i>Neurosurgical Review</i> , <b>1984</b> , 7, 253-8	3.9	8
1	Tauopathy in the APP <sup>swe</sup> /PS1 <sup>E9</sup> mouse model of familial Alzheimer's disease		2